Impact Biomedical (IBO) Income from Continuing Operations (2022 - 2026)
Impact Biomedical's (IBO) quarterly Income from Continuing Operations came in at 2284000.0 in Q1 2026, down 78.72% YoY from 10731441.18 in Q1 2025, and down 54.85% on a QoQ basis from 1475000.0 in Q3 2025.
Impact Biomedical (IBO) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 5 years of Income from Continuing Operations data on file, last reported at 2284000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 78.72% year-over-year to 2284000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 19389000.0 (up 22.51% YoY) and the FY2024 annual result came in at 24770000.0, down 462.06% from the prior year.
- Income from Continuing Operations declined to 2284000.0 in Q1 2026, from 1475000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 4241000.0 in Q3 2024 to a low of 27100000.0 in Q4 2024.
- A 5-year average of 3662600.0 and a median of 1261000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 460.32% in 2024, down 2049.09% in 2024.
- Tracing IBO's Income from Continuing Operations over 5 years: stood at 3366000.0 in 2022, then jumped by 62.54% to 1261000.0 in 2023, then sank by 2049.09% to 27100000.0 in 2024, then soared by 94.56% to 1475000.0 in 2025, then sank by 54.85% to 2284000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 2284000.0 (Q1 2026), 1475000.0 (Q3 2025), and 14352000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 | -700,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -700,000.00 |
| Mar 31, 2026 | -2.28 Mn |
| Sep 30, 2025 | -1.48 Mn |
| Jun 30, 2025 | -14.35 Mn |
| Mar 31, 2025 | -1.28 Mn |
| Dec 31, 2024 | -27.10 Mn |
| Sep 30, 2024 | 4.24 Mn |
| Jun 30, 2024 | -884,000.00 |
| Mar 31, 2024 | -998,000.00 |
| Dec 31, 2023 | -1.26 Mn |
| Sep 30, 2023 | -1.18 Mn |
| Jun 30, 2023 | -1.12 Mn |
| Mar 31, 2023 | -849,000.00 |
| Dec 31, 2022 | -3.37 Mn |
| Sep 30, 2022 | -2.24 Mn |
| Jun 30, 2022 | -799,000.00 |